Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02889861 · ClinicalTrials.gov registry record · Phase 2
IMCgp100-401 Rollover Study
A Phase 2 study, sponsored by Immunocore.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02889861: Clinical Trial Phase 2 study, sponsored by Immunocore.
NCT02889861 is a Phase 2 study that was terminated before completion, run by Immunocore. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02889861, a Phase 2 study, was terminated before completion, sponsored by Immunocore.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
IMCgp100-401 is a rollover study that is designed to provide continued access to IMCgp100 for eligible participants with advanced melanoma who have previously participated in an IMCgp100 study (parent study).
Primary Outcome
Incidence of adverse events was presented as the number of participants with treatment-emergent adverse events (TEAEs). TEAEs were defined as adverse events (AEs) that started or worsened in severity from the date of first dose of the rollover study (regardless of time) up until 90 days after the last dose of study drug of this rollover study. Participants with multiple events in the same category were counted only once in that category. Participants with events in more than 1 category were coun
Interventions
- DRUG IMCgp100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-01-11 |
| Est. Completion | 2019-04-22 |
| Phase | Phase 2 |
Why NCT02889861 stopped before completion
NCT02889861 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which IMCgp100 is the first listed.
NCT02889861 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02889861 about?
NCT02889861 is a clinical study titled "IMCgp100-401 Rollover Study". IMCgp100-401 is a rollover study that is designed to provide continued access to IMCgp100 for eligible participants with advanced melanoma who have previously participated in an IMCgp100 study (parent study).
What is the current status of trial NCT02889861?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2017-01-11. Estimated completion is 2019-04-22.
What interventions are being tested in trial NCT02889861?
The interventions under investigation include: IMCgp100 (DRUG).
Who is sponsoring clinical trial NCT02889861?
This trial is sponsored by Immunocore, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02889861's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI